Anti-TL1A/anti-TNF-[alpha] bispecific antigen binding proteins and uses thereof

The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-[alpha]. Such bispecific antibodies can be in a conventional tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the ant...

Full description

Saved in:
Bibliographic Details
Main Authors HORTTER, MICHELLE, KANNAN, GUNASEKARAN, HSU, HAILING, BELOUSKI, EDWARD J, WALKER, KENNETH W
Format Patent
LanguageChinese
English
Published 16.09.2017
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-[alpha]. Such bispecific antibodies can be in a conventional tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-[alpha] The bispecific antigen binding proteins may also be comprised in a IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-[alpha] antigen binding proteins, and pharmaceutical formulations thereof.
Bibliography:Application Number: TW20165141920